CHronic use of amiodarone aGAinSt implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: Rationale and design of a randomized clinical trial

American Heart Journal

Volumn 166, Issue 6, 2013, Pages

  Martinelli, Martino ^a   Rassi, Anis ^b   Marin Neto, José Antonio ^a   De Paola, Angelo Amato Vincenzo ^c   Berwanger, Otávio ^a   Scanavacca, Maurício Ibraim ^a   Kalil, Roberto ^a   De Siqueira, Sérgio Freitas ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Anis Rassi Hospital   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; BRAZIL; CHAGAS DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK; SCORING SYSTEM; SUDDEN CARDIAC DEATH; ADOLESCENT; CHAGAS CARDIOMYOPATHY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DEATH, SUDDEN, CARDIAC; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BRAZIL; CHAGAS CARDIOMYOPATHY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888636795     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.08.027     Document Type: Article

References (40)

1. A. Rassi Jr., A. Rassi, and J.A. Marin-Neto Chagas disease Lancet 375 2010 1388 1402
2. A. Rassi Jr., A. Rassi, and J. Marcondes de Rezende American trypanosomiasis (Chagas disease) Infect Dis Clin North Am 26 2012 275 291
3. A. Rassi, J.M. Rezende, and A.O. Luquetti Clinical phases and forms of Chagas disease J. Telleria, M. Tibayrenc, American trypanosomiasis (Chagas disease). One hundred years of research 1st edition 2010 Elsevier Inc. Burlington 709 741
4. A. Rassi Jr., A. Rassi, and W.C. Little Chagas' heart disease Clin Cardiol 23 2000 883 889
5. Salvatella R. Organizacion Panamericana de la Salud. Estimacion cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: Organizacion Panamericana de la Salud, Report no. OPS/ HDM/CD/425-06. 2006 [in Spanish].
6. WHO Chagas disease (American trypanosomiasis) fact sheet (revised in June 2010) Wkly Epidemiol Rec 85 2010 334 336
7. F.R. Martins-Melo, C.H. Alencar, and A.N. Ramos Jr. Epidemiology of mortality related to Chagas' disease in Brazil, 1999-2007 PLoS Negl Trop Dis 6 2012 e1508
8. A. Rassi Jr., S.G. Rassi, and A. Rassi Sudden death in Chagas' disease Arq Bras Cardiol 76 2001 75 96
9. I. Mendoza, F. Moleiro, and J. Marques Sudden death in Chagas' disease. [Article in Portuguese] Arq Bras Cardiol 59 1992 3 4
10. S.J. Connolly, A.P. Hallstrom, and R. Cappato Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study Eur Heart J 21 2000 2071 2078
11. K. Nanthakumar, A.E. Epstein, and G.N. Kay Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials J Am Coll Cardiol 44 2004 2166 2172
12. J.A. Ezekowitz, B.H. Rowe, and D.M. Dryden Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction Ann Intern Med 147 2007 251 262
13. A. Rassi Jr. Implantable cardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial J Cardiovasc Electrophysiol 18 2007 1241 1243
14. A. Rassi Jr., A. Rassi, and W.C. Little Development and validation of a risk score for predicting mortality in Chagas' heart disease N Engl J Med 355 2006 799 808
15. M.O. Rocha, and A.L. Ribeiro A risk score for predicting death in Chagas' heart disease N Engl J Med 355 2006 2488 2489
16. V.S. Issa, A.F. Amaral, and F.D. Cruz Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial Circ Heart Fail 3 2010 82 88
17. A. Rassi Jr., and A. Rassi Letter by Rassi et al regarding article, "Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial" Circ Heart Fail 3 2010 e11
18. R. Hidalgo, A.J. Martí-Carvajal, and J.S. Kwong Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy Cochrane Database Syst Rev 11 2012 Nov 14 CD009077
19. F.R. Quiros, C.A. Morillo, and J.P. Casas CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973] Trials 7 2006 21
20. P.C. O'Brien, and T.R. Fleming A multiple testing procedure for clinical trials Biometrics 35 1979 549 556
21. J.N.S. Mathews Introduction to randomized controlled clinical trials 2006 Chapman & Hall/CRC
22. A. Cardinalli-Neto, R.B. Bestetti, and J.A. Cordeiro Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy J Cardiovasc Electrophysiol 18 2007 1236 1240
23. A. Cardinalli-Neto, M.A. Nakazone, and L.V. Grassi Implantable cardioverter-defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy Int J Cardiol 150 2011 94 95
24. M. Martinelli, S.F. Siqueira, and E.B. Sternick Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in Chagas' heart disease Am J Cardiol 110 2012 1040 1045
25. M.P. Barbosa, M.O. da Costa Rocha, and A.B. de Oliveira Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease Europace 15 2013 957 962
26. R. Garillo, O.T. Greco, and O. Oseroff Cardioverter defibrillator implantable as a secondary prevention in the Chagas' disease. The results of the Latin-American Studies ICD LABOR Reblampa 17 2004 [article in Spanish]
27. C.A. Muratore, L.A. Batista Sa, and P.A. Chiale Implantable cardioverter defibrillators and Chagas' disease: results of the ICD Registry Latin America Europace 11 2009 164 168
28. A.L. Ribeiro, P.S. Cavalvanti, and F. Lombardi Prognostic value of signal-averaged electrocardiogram in Chagas disease J Cardiovasc Electrophysiol 19 2008 502 509
29. A. Rassi Jr., A. Gabriel Rassi, and S. Gabriel Rassi Ventricular arrhythmia in Chagas disease. Diagnostic, prognostic, and therapeutic features Arq Bras Cardiol 65 1995 377 387 [in Portuguese]
30. H.C. Doval, D.R. Nul, and H.O. Grancelli Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Lancet 344 1994 493 498
31. J.J. Garguichevich, J.L. Ramos, and A. Gambarte Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA) Am Heart J 130 1995 494 500
32. S.A. Strickberger, J.D. Hummel, and T.G. Bartlett for the AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT J Am Coll Cardiol 41 2003 1707 1712
33. P.A. Chiale, M.S. Halpern, and G.J. Nau Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis Am Heart J 107 1984 656 665
34. V.R. Vorperian, T.C. Havighurst, and S. Miller Adverse effects of low dose amiodarone: a meta-analysis J Am Coll Cardiol 30 1997 791 798
35. S.M. Sopher, and A.J. Camm Adverse effects of amiodarone at low dose: plus ça change J Am Coll Cardiol 30 1997 799 801
36. S.H. Hohnloser, T. Klingenheben, and B.N. Singh Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia Ann Intern Med 121 1994 529 535
37. L. Harris, P. Chatelain, and P. Nokin Pharmacology of amiodarone. In Amiodarone. Pharmacology, pharmacokinetics, toxicology, clinical effects L. Harris, R. Roncucci, 1986 Médecine et Sciences Internationales Paris 23 24
38. B.N. Singh Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent Am J Cardiol 78 4A 1996 41 53
39. B.M. Massie, S.G. Fisher, and M. Radford Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 93 1996 2128 2134
40. G.H. Bardy, K.L. Lee, and D.B. Mark Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237